Clinical Allergy and immunology

1. high prevalence

2. risk factors

3. application of new technologies

3.1. OMICS

3.2. novel, targeted therapies

3.3. cytocxines

3.4. biomarkers

4. Atopic Dermatitis

4.1. anti-inflammatory drugs

4.2. L-13, the IL-4/IL-13 receptor

4.3. TSLP, JAK/STAT

4.4. CRTH2, and IgE

5. Unraveling Urticaria

5.1. recomended Omalizumab, an anti-IgE antibody,

5.2. efficacy 80%

6. impact on physical and psychological health,

7. Asthma

7.1. not associated with smoking

7.2. NSAIDs)

7.3. genotypes as shown for HLA class I and II

7.4. chronic inflammatory disease

7.5. marker of eosinophilic inflammation

7.6. Omalizumab

7.6.1. blocking IL-5

8. Rhinitis

8.1. male predominance

8.2. associated with wheeze

8.3. Immunotherapy to ragweed pollen

8.4. pollinosis, a subgroup

8.5. absence of specific IgE antibodies

8.6. cow’s milk, egg yolk, egg white, and soy,

9. Food A.

9.1. a 14-kDa protein identified as oleosin

9.2. high levels of IgE to rPen a 1 and rDer p 10;

9.3. OFC tests